NCT06512311View on ClinicalTrials.gov

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

NARecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2031

Conditions
Glioblastoma
Interventions
DIAGNOSTIC_TEST

CBMed Drug Screening Plattform

The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.

Trial Locations (1)

1090

RECRUITING

AKH Vienna, Department for Internal Medicine I, Oncology, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER